HRGN — Harvard Apparatus Regenerative Technology Share News
0.000.00%
Last trade - 00:00- $39.80m
- $39.95m
- $0.70m
Brief: Biostage says provides regulatory update of Cellspan Esophageal Implant
Brief: Biostage posts Q2 loss per share $0.17
Brief: Biostage says files for stock shelf of up to $20 million - SEC filings
Brief: Biostage says cellspan implants being advanced, tested in preclinical studies
Brief: Biostage files for FDA orphan drug designation for cellspan esophageal implant
Brief: Biostage CEO provides mid-year update to shareholders
Brief: Empery Asset Management reports 5.53 pct stake in Biostage
Brief: Biostage Director Thomas Robinson reports open market purchase
Brief: Biostage announces $5 million at-the-market offering
Brief: Biostage regenerates esophagus in pre-clinical work with Mayo Clinic
Brief: Biostage Q1 loss per share $0.18
Brief: Harvard Apparatus Regenerative Technology Q4 loss $0.17/share
Brief: Harvard Apparatus Regenerative Technology sauys selling stockholder Aspire Capital Fund may sell up to 2.7 mln shares
Brief: HART secures stock purchase facility with Aspire Capital
Brief: Hart Q3 loss per share $0.19
Brief: Harvard Apparatus Regenerative Technology Q2 loss per share $0.44
Brief: Harvard Apparatus announces promotion of Saverio La Francesca
Brief: Harvard Apparatus Regenerative Technology says Thomas McNaughton appointed interim CEO
Brief: Harvard Apparatus Q4 loss per share $0.36